About Calliditas Therapeutics
genkyotex has become a wholly owned subsidiary of calliditas and have been delisted from the euronext stock exchanges. genkyotex’s lead product candidate, setanaxib, is a first-in-cl... Read more
genkyotex has become a wholly owned subsidiary of calliditas and have been delisted from the euronext stock exchanges. genkyotex’s lead product candidate, setanaxib, is a first-in-cl... Read more